TipRanks
Go Ultimate55% OFF

Tevogen Bio Holdings (G280) AI Stock Analysis

DE:G280

Tevogen Bio Holdings

(Frankfurt:G280)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
T-cell Immunotherapy PlatformA focused T-cell immunotherapy platform gives Tevogen a defined scientific direction and the potential to develop multiple cell-therapy candidates. Continued research, clinical translation, and eventual commercialization could create a foundation for future revenue if development succeeds.
Negative Factors
Pre-Revenue BusinessZero revenue confirms that Tevogen remains pre-commercial and has not yet demonstrated product-market monetization. Until a therapy reaches commercialization and generates sales, the business depends on development progress and external capital rather than internally generated operating income.

Tevogen Bio Holdings (G280) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:G280-81.51%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 24.57M
Dividend Yield
―
Average Volume (3M)
20
Price to Earnings (P/E)
-1.0
Beta (1Y)
1.11
Revenue Growth
―
EPS Growth
36.06%
Country
Germany
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Tevogen Bio Holdings Business Overview & Revenue Model

Company Description

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T...

Tevogen Bio Holdings Risk Analysis

Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1..An investment in our common stock involves a high degree of risk. You should carefully consider the risks set forth in the “Risk Factors” section of our Annual Report, other information set forth in this Report, and the additional information in the other reports we file with the SEC. If any of the risks contained in those reports occur, our business, results of operations, financial condition, and liquidity could be harmed, the value of our securities could decline, and you could lose all or part of your investment. Except as described below, there have been no material changes in the risk factors set forth in the “Risk Factors” section of our Annual Report.Q2, 2026
2. If we fail to meet Nasdaq’s continued listing requirements, our common stock and our outstanding public warrants to purchase common stock could be delisted.Our common stock and our public warrants are listed on Nasdaq. We are required to meet specified financial and other requirements in order to maintain such listing, including a requirement that the closing bid price for our common stock remain above $1.00 and that the market value of our common stock is at least $50 million and the market value of publicly held shares of our common stock is at least $15 million.On April 16, 2026, we received a letter from Nasdaq’s Listing Qualifications Staff (the “Staff”) notifying us that we no longer meet Nasdaq’s $50 million minimum market value for listed securities requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”) for continued listing on the Nasdaq Global Market based on Nasdaq’s review of the market value of the Company’s listed securities for the previous 30 consecutive business days. In addition, on April 17, 2026, we received a letter from the Staff notifying us that we no longer meet Nasdaq’s $15 million minimum market value of publicly held shares requirement under Nasdaq Listing Rules 5450(b)(2)(C) and (3)(C) (the “MVPHS Requirement”, and together with the MVLS Requirement, the “Requirements”) based on Nasdaq’s review of the market value of the Company’s publicly held shares for the previous 30 consecutive business days. The notifications have no immediate effect on the Company’s listing or trading on the Nasdaq Global Market.Nasdaq has provided us a period of 180 calendar days to regain compliance with each Requirement, or until October 13, 2026 for the MVLS Requirement (the “MVLS Compliance Date”) and October 14, 2026 for the MVPHS Requirement (the “MVPHS Compliance Date” and, together with the MVLS Compliance Date, the “Compliance Dates”). If, at any time before the applicable Compliance Date, our market value of listed securities closes at $50 million or more or our market value of publicly held shares closes at $15 million or more for a minimum of 10 consecutive business days and up to generally not more than 20 consecutive business days, the Staff will provide written notification to us that we have regained compliance with the applicable Requirement.We intend to actively monitor the market value of our listed securities and publicly held shares. We may evaluate and consider available options for regaining compliance with the Requirements, as well as applying for a transfer to The Nasdaq Capital Market. However, there can be no assurance that we will take any specific action or be able to regain compliance with either Requirement or otherwise maintain compliance with Nasdaq listing rules.If we fail to regain compliance with the Requirements or to meet other Nasdaq continued listing requirements, Nasdaq may take steps to delist our securities. Such a delisting would likely have a negative effect on the price of our securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our securities from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements. Additionally, if our securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if our securities were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.Q2, 2026

Tevogen Bio Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:G280 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NVCTNVCT56Neutral$603.26M-14.11-169.47%――-13.52%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
STTKSTTK45Neutral$558.02M-10.90-43.57%―-66.63%57.89%
NKTXNKTX42Neutral$111.73M-0.99-39.64%――-6.70%
CCCCCCCC41Neutral$414.59M-3.37-45.45%―2.33%36.86%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%DE:G280NKTXCCCCSTTKNVCTACTUDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:G280 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:G280Tevogen Bio Holdings Inc.4.52-22.38-83.20%
NKTXNkarta, Inc.1.56-0.51-24.64%
CCCCC4 Therapeutics, Inc.3.370.8935.89%
STTKShattuck Labs, Inc.5.563.57179.40%
NVCTNuvectis Pharma, Inc.18.4812.12190.57%
ACTUActuate Therapeutics, Inc.0.34-6.37-95.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.